These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14607383)

  • 1. Pharmacology of cytotoxic agents: a helpful tool for building dose adjustment guidelines in the elderly.
    Tranchand B; Laporte S; Glehen O; Freyer G
    Crit Rev Oncol Hematol; 2003 Nov; 48(2):199-214. PubMed ID: 14607383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacology of anticancer drugs in the elderly: tools for dose-adjustment].
    Tranchand B; Falandry C; You B; Girard P; Ribba B; Tod M; Freyer G
    Bull Cancer; 2008 May; 95 FMC Onco():F21-7. PubMed ID: 18511363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of anticancer drugs in the elderly population.
    Wildiers H; Highley MS; de Bruijn EA; van Oosterom AT
    Clin Pharmacokinet; 2003; 42(14):1213-42. PubMed ID: 14606930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic alterations in the geriatric patient.
    Delafuente JC
    Consult Pharm; 2008 Apr; 23(4):324-34. PubMed ID: 18454589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated PK-PD and agent-based modeling in oncology.
    Wang Z; Butner JD; Cristini V; Deisboeck TS
    J Pharmacokinet Pharmacodyn; 2015 Apr; 42(2):179-89. PubMed ID: 25588379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
    Gurney H
    J Clin Oncol; 1996 Sep; 14(9):2590-611. PubMed ID: 8823340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.
    Lucas CJ; Martin JH
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S78-S98. PubMed ID: 28921641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.
    Kintzel PE; Dorr RT
    Cancer Treat Rev; 1995 Jan; 21(1):33-64. PubMed ID: 7859226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
    Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
    Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population approaches in paediatrics.
    Chatelut E
    Fundam Clin Pharmacol; 2008 Dec; 22(6):575-8. PubMed ID: 19049657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients.
    Avramis VI; Spence SA
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):239-47. PubMed ID: 17414566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia.
    Henrich A; Joerger M; Kraff S; Jaehde U; Huisinga W; Kloft C; Parra-Guillen ZP
    J Pharmacol Exp Ther; 2017 Aug; 362(2):347-358. PubMed ID: 28600397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area.
    Kaestner SA; Sewell GJ
    Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):23-37. PubMed ID: 17305252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anticancer drugs in the elderly: an overview.
    Lonardi S; Bortolami A; Stefani M; Monfardini S
    Drugs Aging; 2007; 24(5):395-410. PubMed ID: 17503896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy?
    Newell DR
    Ann Oncol; 1994; 5 Suppl 4():9-14; discussion 15. PubMed ID: 8060901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of antineoplastic agents in older cancer patients.
    Lichtman SM; Skirvin JA
    Oncology (Williston Park); 2000 Dec; 14(12):1743-55; discussion 1755, passim. PubMed ID: 11204376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose adjustment and supportive care before and during treatment.
    Brunello A; Loaldi E; Balducci L
    Cancer Treat Rev; 2009 Oct; 35(6):493-8. PubMed ID: 19493625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug dosage in the elderly. Is it rational?
    Turnheim K
    Drugs Aging; 1998 Nov; 13(5):357-79. PubMed ID: 9829164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.